Percutaneous Needle-Based OCT Differentiates Renal Masses

This article originally appeared here.
Share this content:
Percutaneous Needle-Based OCT Differentiates Renal Masses
Percutaneous Needle-Based OCT Differentiates Renal Masses

FRIDAY, April 29, 2016 (HealthDay News) -- Percutaneous needle-based optical coherence tomography (OCT) can differentiate renal masses, according to a study published in the May issue of The Journal of Urology.

Peter G.K. Wagstaff, from AMC University Hospital in the Netherlands, and colleagues performed percutaneous needle-based OCT of the kidney in patients presenting with a solid renal mass. They obtained pathology specimens as biopsies and/or resection specimens. In order to derive the attenuation coefficient (µOCT) values of oncocytoma and renal cell carcinoma, they correlated optical coherence tomography results of 40 patients to pathology results of the resected specimens.

The researchers found that the median µOCT was significantly lower for oncocytoma versus renal cell carcinoma. In receiver operating curve (ROC) analysis, a µOCT cutoff value of 3.8 mm−1 could differentiate between oncocytoma and renal cell carcinoma with sensitivity, specificity, positive predictive value, and negative predictive value of 86, 75, 97, and 37 percent, respectively; 0.81 was the area under the ROC. The median µOCT was significantly lower for oncocytoma versus clear cell renal cell carcinoma and papillary renal cell carcinoma (P = 0.049 and 0.027, respectively).

"We demonstrated that the µOCT is significantly higher in renal cell carcinoma versus oncocytoma, with ROC analysis showing promising results for their differentiation," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »